Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings Inc. reported that executive W. Richard Staub, President of Research & Development Solutions, received a grant of stock appreciation rights covering 26,088 shares of common stock on February 9, 2026. These rights have a $192.67 exercise price and vest in three equal annual installments beginning February 9, 2027.
IQVIA Holdings Inc. reported that executive officer Eric Sherbet, Executive Vice President and General Counsel, was granted a stock appreciation right on its common stock. The award covers 12,112 shares at a conversion or exercise price of $192.67 per share and was granted on February 9, 2026.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027 and expires on February 9, 2036. Following this grant, 12,112 derivative securities tied to IQVIA common stock are beneficially owned directly by the reporting person.
IQVIA Holdings Inc. reported that officer Bhavik Patel, President, MedTech and Consumer Health, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 derivative securities tied to 11,180 shares of common stock at a conversion or exercise price of $192.67.
These stock appreciation rights were acquired as a grant or award and are held directly. The award vests in three annual installments beginning on February 9, 2027, meaning the rights become exercisable over a three-year period starting on that date.
IQVIA Holdings Inc. executive Bernd Haas, EVP, AI and Technology Solutions, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 stock appreciation rights with a conversion or exercise price of $192.67 per right.
These stock appreciation rights vest in three annual installments beginning on February 9, 2027, and are held as a direct ownership position. After this grant, Haas beneficially owned 11,180 derivative securities tied to IQVIA common stock.
IQVIA Holdings Inc. reported that officer Alistair Grenfell received a grant of 26,088 stock appreciation rights on February 9, 2026, at an exercise price of $192.67 per right. These rights vest in three annual installments beginning on February 9, 2027, and are scheduled to expire on February 9, 2036. Following this award, Grenfell beneficially owns 26,088 derivative securities directly.
IQVIA Holdings executive Michael J. Fedock received a new equity award. On February 9, 2026, he was granted a stock appreciation right covering 18,634 shares of IQVIA common stock at an exercise price of $192.67 per share, expiring on February 9, 2036.
The stock appreciation right was acquired as a grant and is held directly. According to the terms, it will vest in three annual installments beginning on February 9, 2027, aligning the senior vice president of FP&A’s compensation with long-term shareholder value.
IQVIA Holdings Inc. reported that officer Keriann Cherofsky received a grant of stock appreciation rights. On February 9, 2026, she was awarded 2,795 stock appreciation rights with an exercise price of $192.67 per share, held directly.
The grant vests in three equal annual installments beginning on February 9, 2027. After this transaction, Cherofsky beneficially owned 2,795 derivative securities related to IQVIA common stock. She serves as SVP, Corporate Controller.
IQVIA Holdings executive James G. Berkshire received a stock appreciation right award covering 11,180 shares of common stock. The award was granted on February 9, 2026 at an exercise price of $192.67 per share and expires on February 9, 2036.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027. Following this grant, Berkshire beneficially owns 11,180 derivative securities directly, in his role as EVP, Global Infrastructure and Operations.
IQVIA Holdings Inc. Director and Chairman, Chief Executive Officer & President Ari Bousbib reported receiving a grant of stock appreciation rights on February 9, 2026. The award covers 78,264 derivative securities tied to the company’s common stock at a conversion or exercise price of $192.67 per share.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027, meaning the right becomes exercisable over a three-year period rather than all at once. Following this grant, Bousbib directly holds 78,264 stock appreciation rights related to IQVIA common stock.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Leslie Wims Morris received a grant of 159 deferred share units on February 9, 2026. Each deferred share is convertible into one share of common stock upon settlement under the company’s Non-Employee Director Deferral Plan. Settlement occurs when Morris ceases to be a director, upon a change in control of the company, or upon death, and there is no expiry date. Following this grant, Morris directly beneficially owns 4,894 deferred share units.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
